

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊 生 物 科 技 有 限 公 司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

FURTHER DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS AND ANNUAL REPORT

This announcement is made by Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 22 September 2022 in relation to, among other matters, the delay in publication of the audited annual results of the Group for the eighteen months ended 30 June 2022, and the announcement of the Company dated 30 September 2022 in relation to the unaudited annual results of the Group for the eighteen months ended 30 June 2022 (the “**Announcements**”). Capitalised terms used herein shall have the same meaning as those defined in the Announcements unless stated otherwise.

As set out in the Announcements, due to the outbreak of COVID-19 in Shandong Province since late August 2022, the local government implemented stringent travel and quarantine restrictions and these restrictions adversely affected the Auditors to complete the audit procedures of the subsidiaries of the Company, namely Weifang Century-Light Biology Science Company Limited and Weifang Jia You You Zhi Company Limited, in Shandong Province (the “**PRC Subsidiaries**”).

On or about the period of the holidays for National Day of the People’s Republic of China (the “**PRC**”) till mid-October 2022, a number of acquired cases for COVID-19 were discovered in Weifang City including Changle County, the PRC. The office and production plant of the PRC Subsidiaries are located at Changle County. The local government in the region continues to implement stringent travel, quarantine restrictions and other measures such as lockdown and mass mandatory testing (collectively, the “**Measures**”). The traveling of the Auditors and the staff of the PRC Subsidiaries in the region have been seriously affected, and the situation continues as at the date of this announcement. As a result, the auditing process, including audit confirmation procedures with some banks, face-to-face collaborative enquiry with other independent third parties that requires traveling to different locations in Shandong Province

and vouching of the remaining supporting documents for the financial statements of the PRC Subsidiaries, has been adversely affected. In the current time, the Company does not have information as to when the Measures implemented by the local government will be lifted. After communicating with the Auditors, on the assumption that the Measures implemented by the local government could be mostly eased or lifted near or before the end of October 2022, the Auditors will require two more weeks to complete their audit work. On this basis, the Company estimates that the publication of the audited annual results of the Group for the eighteen months ended 30 June 2022 would be made on or before 14 November 2022 and the despatch of the annual report to the shareholders of the Company would be made on or before 28 November 2022 as additional time is required to, among other things, prepare the information for inclusion in the annual report for complying with the provisions set out in Appendix 16 to the Listing Rules, and arrange bulk-printing of the annual report.

The Company will apply to The Stock Exchange of Hong Kong Limited for waiver from strict compliance with Rule 13.46(2)(a) of the Listing Rules to despatch the annual report to the shareholders of the Company not later than four months from the end of the financial year of the Company. On the basis that the Company will hold its annual general meeting on or before 31 December 2022, the Company complies with the Rule 13.46(2)(b) of the Listing Rules.

As at the date of this announcement, save as disclosed above, the Auditors have not indicated any other major audit issues or audit qualification to the results and financial position of the Group. The Company will, on its best effort, cooperate with the Auditors to enable them to complete their audit work as soon as possible. There have been no unpublished inside information identified as at the date of this announcement.

The Company will publish further announcement to keep the shareholders of the Company and potential investors of the Company informed as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Wai Chun Bio-Technology Limited
Chan Cheuk Ho
Executive Director

Hong Kong, 21 October 2022

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Chan Cheuk Ho and two independent non-executive Directors, namely Mr. Wan Bo and Ms. Hong Ting.